The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Open accessAbstract
Cytokines in the tumor necrosis factor (TNF) family regulate development and function of the immune system. We have isolated a new member of this family, designated Apo-2 ligand (Apo-2L), via an expressed sequence tag. Apo-2L is a 281-amino acid protein, related most closely to Fas/Apo-1 ligand. Transfected Apo-2L is expressed at the cell surface with its C terminus exposed, indicating a type II transmembrane protein topology. Like Fas/Apo-1 ligand and TNF, the C-terminal extracellular region of Apo-2L (amino acids 114-281) exhibits a homotrimeric subunit structure. Soluble Apo-2L induces extensive apoptosis in lymphoid as well as non-lymphoid tumor cell lines. The effect of Apo-2L is not inhibited by soluble Fas/Apo-1 and TNF receptors; moreover, expression of human Fas/Apo-1 in mouse fibroblasts, which confers sensitivity to induction of apoptosis by agonistic anti-Fas/Apo-1 antibody, does not confer sensitivity to Apo-2L. Hence, Apo-2L acts via a receptor which is distinct from Fas/Apo-1 and TNF receptors. These results suggest that, along with other family members such as Fas/Apo-1 ligand and TNF, Apo-2L may serve as an extracellular signal that triggers programmed cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., & Henson, P. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.7.2207 · Cited by 3,316
Koopman, G., Reutelingsperger, C., Kuijten, G., Keehnen, R., Pals, S., & van Oers, M. (1994) · Blood · doi:10.1182/blood.v84.5.1415.1415 · Cited by 2,681
Social controls on cell survival and cell death
Raff, M. C. (1992) · Nature · doi:10.1038/356397a0 · Cited by 2,604
Mechanisms and Genes of Cellular Suicide
Steller, H. (1995) · Science · doi:10.1126/science.7878463 · Cited by 2,479
Baculovirus expression vectors: a laboratory manual.
O’Reilly, D. R., Miller, L. K., & Luckow, V. A. (1992) · Oxford University Press eBooks · Cited by 2,242
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,887
An analysis of vertebrate mRNA sequences: intimations of translational control.
Kozak, M. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.4.887 · Cited by 1,635
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M., & Krammer, P. H. (1995) · Nature · doi:10.1038/373438a0 · Cited by 1,609
Yonehara, S., Ishii, A., & Yonehara, M. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.5.1747 · Cited by 1,400
Cited by
Items 101–117 of 117
A Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL
Hymowitz, S. G., O'Connell, M. P., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., de Vos, A. M., & Kelley, R. F. (2000) · Biochemistry · doi:10.1021/bi992242l · Cited by 261
Self-citationEradication of established tumors in mice by a combination antibody-based therapy
Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F., Okumura, K., Yagita, H., & Smyth, M. J. (2006) · Nature Medicine · doi:10.1038/nm1405 · Cited by 257
TRAIL and its receptors as targets for cancer therapy
Yagita, H., Takeda, K., Hayakawa, Y., Smyth, M. J., & Okumura, K. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02181.x · Cited by 254
Genetic Engineering of Mesenchymal Stem Cells and Its Application in Human Disease Therapy
Hodgkinson, C. P., Gomez, J. A., Mirotsou, M., & Dzau, V. J. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.165 · Cited by 150
Huang, K., Zhang, J., O’Neill, K. L., Gurumurthy, C. B., Quadros, R. M., Tu, Y., & Luo, X. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.711051 · Cited by 136
(2001) · PubMed · Cited by 130
The linear ubiquitin chain assembly complex regulates TRAIL‐induced gene activation and cell death
Lafont, E., Kantari‐Mimoun, C., Draber, P., De Miguel, D., Hartwig, T., Reichert, M., Kupka, S., Shimizu, Y., Taraborrelli, L., Spit, M., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201695699 · Cited by 114
Bellail, A. C., Olson, J. J., Yang, X., Chen, Z. J., & Hao, C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0172 · Cited by 113
“The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) (1, 2) executes the innate and adaptive immunity in the process of tumor immunosurveillance (3).”
BackgroundStem cells as vectors for antitumour therapy
Loebinger, M. R., & Janes, S. M. (2010) · Thorax · doi:10.1136/thx.2009.128025 · Cited by 109
“59 60 This novel ligand was found to cause apoptosis selectively in tumour cells, sparing normal cells.”
BackgroundSensitivity of Ewing's sarcoma to TRAIL-induced apoptosis
Kontny, H. U., Hämmerle, K., Klein, R., Shayan, P., Mackall, C. L., & Niemeyer, C. M. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400836 · Cited by 90
“± 22 TRAIL appears to be able to induce apoptosis in a wide range of transformed cell lines.(10,11) The systemic application of TRAIL into mice has been shown to be nontoxic and able to suppress the growth of a human mammary adenocarcinoma.”
BackgroundNazim, U. M., Moon, J.-H., Lee, J.-H., Lee, Y.-J., Seol, J.-W., Eo, S.-K., Lee, J.-H., & Park, S.-Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8048 · Cited by 58
Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells
Shlyakhtina, Y., Pavet, V., & Gronemeyer, H. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.423 · Cited by 56
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
“rhTRAIL induces selective apoptosis in cancer cells and leaves the normal cells unharmed [170,171].”
BackgroundExpression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells
Lippa, M. S., Strockbine, L. D., Le, T. T., Branstetter, D. G., Strathdee, C. A., & Holland, P. M. (2007) · Apoptosis · doi:10.1007/s10495-007-0076-6 · Cited by 42
“Apo2L/TRAIL is a type II transmembrane protein of the TNF superfamily that was identified based on sequence homology to TNF and Fas ligand (FasL) [1, 2].”
BackgroundTherapeutics Targeting the Core Apoptotic Machinery
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers · doi:10.3390/cancers13112618 · Cited by 26
Farooqi, A. A., Rakhmetova, V. S., Kapanova, G., Tashenova, G., Tulebayeva, A., Akhenbekova, A., Ibekenov, O., Turgambayeva, A., & Xu, B. (2023) · Molecules · doi:10.3390/molecules28052231 · Cited by 25
CHAUDHARI, A. A., SEOL, J.-W., KANG, S.-J., & PARK, S.-Y. (2008) · Journal of Veterinary Medical Science · doi:10.1292/jvms.70.537 · Cited by 22
“TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a recently identified member of the TNF family that also activates the cognate receptor molecules through a trimerization process that is similar to other members of the TNF family [19, 23].”
Background
Metadata
- Authors
- Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1996-05
- Volume
- 271
- Issue
- 22
- Pages
- 12687-12690
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2056217426
- Cited by
- 1,793
- References
- 28
- FWCI
- 17.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.